Target intelligence / Profile preview

Autophagy–Lysosome Pathway (ALP)

Target
ALP
Molecular classification
Intracellular degradation system, Protein degradation pathway, Cellular recycling pathway
01

Overview

The autophagy–lysosome pathway (ALP) is a fundamental intracellular degradation system responsible for the breakdown and recycling of macromolecules, damaged organelles, protein aggregates, and other cellular debris. This process is essential for maintaining cellular homeostasis, especially under stress conditions or during nutrient deprivation. It involves the formation of autophagosomes, their fusion with lysosomes, and the subsequent degradation of the autophagosomal contents. The pathway encompasses several forms, including macroautophagy, selective autophagy (e.g., mitophagy, aggrephagy), chaperone-mediated autophagy (CMA), and microautophagy. Key molecular players include ATG proteins, LC3/ATG8 family members, SNAREs, and RAB GTPases. The ALP serves several critical functions, including the degradation/recycling of long-lived or misfolded proteins, the removal of damaged organelles, and defense against pathogens. Failure or dysregulation leads to accumulation of toxic materials implicated in neurodegenerative diseases like Parkinson’s disease. Modulating this pathway has emerged as a promising therapeutic strategy in neurodegenerative disorders.

Other names
Autophagy pathwayLysosomal degradation pathwayMacroautophagySelective autophagyMitophagyAggrephagyChaperone-mediated autophagyCMAMicroautophagyPexophagyLipophagyXenophagy
02

Mechanism of action

Modulation of autophagy flux (e.g., induction or inhibition of autophagy)

03

Biological functions

Degradation and recycling of macromoleculesRemoval of damaged organellesProtein homeostasisCellular defense against pathogensRegulation of energy balanceProteostasis
04

Disease associations

Neurodegenerative diseases (e.g., Parkinson's disease)CancerAgingInfectionLysosomal storage disorders
05

Safety considerations

Off-target effects due to modulation of other cellular pathwaysPotential for drug resistanceContext-dependent effects (autophagy can be pro-survival or pro-death)Limited understanding of long-term consequences of autophagy modulation
06

Interacting drugs

Rapamycin

4 more in the full profile.

07

Biomarkers

LC3-II levelsp62/SQSTM1 levelsLAMP1/LAMP2 expressionATG protein expression

Beyond the preview

Go deeper on Autophagy–Lysosome Pathway (ALP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autophagy–Lysosome Pathway (ALP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call